台股 » 個股 » 健亞 » 籌碼相關 » 券商分點績效 » 券商分點個股進出

健亞

(4130)
可現股當沖
  • 股價
    23.85
  • 漲跌
    --
  • 漲幅
    0.00%
  • 成交量
    311
  • 產業
    上櫃 生技醫療類股
  • 150人加入追蹤

    立即追蹤

  • 本地時間:13:30

     
健亞 (4130)籌碼相關-德信-三重 券商分點個股進出
券商分點績效/獲利分析

透過統計各券商分點在長期買賣某個股的操作績效,來找出真正獲利的贏家所在券商分點,進而追蹤此贏家所操作的股票與軌跡。

德信-三重 券商分點個股進出

日期買進張數買進均價賣出張數賣出均價收盤價買賣超60日均量成交佔比 大量交易提示
2020/12/3100.00529.9029.80-5553-0.90%
2020/12/03131.0000.0031.0011,1710.09%
2020/10/29229.5500.0029.5021,8160.11%
2020/10/261.730.4200.0030.051.72,2150.08%
2020/09/2500.00131.4531.50-16,363-0.02%
2020/09/10837.75837.5836.6507,2130.00%
2020/09/09137.00138.2039.1007,4420.00%
2020/09/04532.3000.0033.2557,5520.07%
2020/08/21235.7500.0035.6527,5540.03%
2020/08/06239.80439.7839.00-27,562-0.03%
2020/08/05240.15540.3240.10-37,516-0.04%
2020/08/04240.65840.8339.70-67,471-0.08%
2020/08/03540.84340.8541.2027,4270.03%
2020/07/31239.55239.8040.0507,3530.00%
2020/07/2900.00340.0039.50-37,262-0.04%
2020/07/28136.1500.0037.6016,9550.01%
2020/07/27138.0000.0036.6016,7960.01%
2020/07/23142.45142.7042.7006,5670.00%
2020/07/22144.50343.7043.10-26,435-0.03%
2020/07/2100.00143.4041.85-16,294-0.02%
2020/07/20642.78342.5042.2536,1620.05%
2020/07/172947.121347.2544.10165,9220.27%
2020/07/16148.952750.0348.95-265,639-0.46%
2020/07/155848.153849.4747.50205,3310.38%
2020/07/14248.50150.1048.1514,6900.02%
2020/07/13252.9000.0053.5024,4640.04%
2020/07/10647.89848.6448.65-24,130-0.05%
2020/07/09444.2500.0044.2543,6960.11%
2020/07/0800.002039.3440.25-203,681-0.54%
2020/07/062037.0000.0037.95203,6380.55%
2020/06/18339.602441.9640.20-213,697-0.57%
2020/06/172040.30136.2540.30193,3400.57%
2020/06/16836.361236.6536.65-43,048-0.13%
2020/06/1500.00334.0334.30-32,715-0.11%
2020/06/12231.00129.3031.2012,6280.04%
2020/06/08528.4900.0028.3552,1880.23%
2020/06/0200.00226.9026.80-22,146-0.09%
2020/05/29127.7000.0027.7012,1320.05%
2020/05/271027.4000.0027.25102,1360.47%
2020/05/22328.5000.0028.4032,0680.15%
2020/05/21529.48529.5529.0502,0390.00%
2020/05/19227.2000.0027.6521,8520.11%
2020/05/11226.8000.0026.5521,7510.11%
2020/04/30127.2000.0027.7011,4200.07%
2020/04/21226.7000.0026.5021,2650.16%
2020/04/1400.00131.6531.15-11,064-0.09%
2020/04/1300.00129.6530.50-1998-0.10%
2020/04/10228.9500.0028.9029540.21%
2020/04/09129.30130.5529.7009210.00%
2020/04/06130.10231.0329.70-1805-0.12%
2020/04/01129.6500.0029.6517640.13%
2020/03/30229.003031.0530.60-28648-4.31%
2020/03/25224.05224.2524.5003920.00%
2020/03/16221.0000.0020.2022810.71%
2020/02/240.924.5000.0024.650.91430.61%
2020/02/03223.8000.0023.9521501.33%
2020/01/30525.5600.0025.4051493.34%
2019/10/3000.00124.7024.65-1135-0.74%
2019/10/14223.8000.0023.8021561.28%
2019/10/09123.8000.0023.6511590.63%
2019/07/1100.00129.0029.00-1152-0.66%
2019/07/01129.0000.0028.9511530.65%
2019/05/14327.6500.0027.8533400.88%
2019/03/1500.00629.7129.60-6419-1.43%
2019/03/0800.00730.9530.30-7429-1.63%
2019/03/07130.8500.0030.8514050.25%
2019/02/151231.0300.0030.00123413.51%
2019/01/02528.5000.0028.2053041.64%
2018/10/3000.00127.3527.20-11,163-0.09%
2018/10/26128.4500.0027.8511,1620.09%
2018/10/1800.00130.4029.50-11,145-0.09%
2018/10/08131.9000.0032.0011,0850.09%
2018/10/0200.00134.8034.30-1989-0.10%
2018/09/27535.57535.5934.9008720.00%
2018/09/26134.4000.0034.5016420.16%
2018/09/2100.00531.3531.45-5611-0.82%
2018/09/17531.7000.0031.2055740.87%
2018/09/1300.00532.9031.85-5555-0.90%
2018/09/1200.00133.1532.50-1525-0.19%
2018/09/11531.1300.0030.9554711.06%
2018/09/101033.94433.7332.6064371.37%
2018/06/0100.00136.4535.65-11,576-0.06%
2018/05/08137.0500.0037.5011,4860.07%
2018/05/0200.00137.2036.85-11,451-0.07%
2018/04/26337.25235.7035.6011,4190.07%
2018/04/2400.00137.5036.65-11,385-0.07%
2018/04/23138.9500.0038.6011,3690.07%
2018/04/2000.00137.4537.45-11,363-0.07%
2018/04/1900.00137.8037.65-11,377-0.07%
2018/04/18136.5000.0036.6011,3570.07%
2018/04/13338.8800.0037.7031,3260.23%
2018/04/101641.091441.0538.6021,2400.16%
2018/04/09240.50540.0940.50-31,135-0.26%
2018/04/031039.851439.9039.35-41,068-0.37%
2018/03/2900.00138.5037.80-1811-0.12%
2018/03/28938.0800.0037.9597591.19%
2018/03/27238.0000.0037.4027160.28%
新藥研發 浩鼎子公司抗癌新藥申請一期臨床 健亞明年完成試驗Anue鉅亨-2022/09/12
健亞 相關文章